BLOOD CANCER UNITED INC: Form 990, tax year 2018

View the entire original 990 at ProPublica ↗

Organization: BLOOD CANCER UNITED INC (EIN 13-5644916)
Tax period: 2018-07-01 to 2019-06-30
Filed: 2020-02-04
IRS object ID: 202010359349301421
Schema version: 2018v3.2
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2020-02-04T16:20:15-06:00	ReturnTs
Tax Period End	2019-06-30	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	135565207	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	KPMG LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	345 PARK AVENUE	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	101540102	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2018-07-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	135644916	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	THE LEUKEMIA & LYMPHOMA SOCIETYINC	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	LEUK	BusinessNameControlTxt
Phone	9149495213	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	3 INTERNATIONAL DRIVE	AddressLine1Txt
City	RYE BROOK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10573	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	GORDON MILLER JR	PersonNm
Person Title	EVP CHIEF FIN OFFICE	PersonTitleTxt
Phone	9148218908	PhoneNum
Signature	2020-02-04	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	DAVID M HIGHFILL	PreparerPersonNm
PTIN	P01517891	PTIN
Phone	2127589700	PhoneNum
Preparation	2020-02-04	PreparationDt

Filing Security Information FilingSecurityInformation

IP Address IPAddress

Field	Value	IRS element (for citing)
I Pv4 Address	165.225.38.214	IPv4AddressTxt

Field	Value	IRS element (for citing)
IP	2020-02-04	IPDt
IP Tm	17:19:23	IPTm
Filing License Type	P	FilingLicenseTypeCd
At Submission Creation Device Id	64563121E8AEE22D36B9E57E374C7CF58728201C	AtSubmissionCreationDeviceId
At Submission Filing Device Id	64563121E8AEE22D36B9E57E374C7CF58728201C	AtSubmissionFilingDeviceId

Field	Value	IRS element (for citing)
Tax	2018	TaxYr
Build TS	2020-09-23 17:36:50Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	LOUIS J DEGENNARO	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	3 INTERNATIONAL DRIVE SUITE 200	AddressLine1Txt
City	RYE BROOK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10573	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$490,517,231	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.LLS.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1949	FormationYr
Legal Domicile State	NY	LegalDomicileStateCd
Activity Or Mission	OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.	ActivityOrMissionDesc
Voting Members Governing Body	25	VotingMembersGoverningBodyCnt
Voting Members Independent	25	VotingMembersIndependentCnt
Total Employee	1402	TotalEmployeeCnt
Total Volunteers	3000000	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
PY Contributions Grants	$419,570,497	PYContributionsGrantsAmt
CY Contributions Grants	$372,750,094	CYContributionsGrantsAmt
PY Program Service Revenue	$9,230,125	PYProgramServiceRevenueAmt
CY Program Service Revenue	$14,936,342	CYProgramServiceRevenueAmt
PY Investment Income	$9,920,211	PYInvestmentIncomeAmt
CY Investment Income	$8,619,914	CYInvestmentIncomeAmt
PY Other Revenue	$133,928	PYOtherRevenueAmt
CY Other Revenue	-$85,198	CYOtherRevenueAmt
PY Total Revenue	$438,854,761	PYTotalRevenueAmt
CY Total Revenue	$396,221,152	CYTotalRevenueAmt
PY Grants And Similar Paid	$157,849,965	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$146,416,708	CYGrantsAndSimilarPaidAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$104,079,229	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$113,204,908	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$5,748,936	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$5,823,217	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$48,650,051	CYTotalFundraisingExpenseAmt
PY Other Expenses	$88,772,222	PYOtherExpensesAmt
CY Other Expenses	$101,876,640	CYOtherExpensesAmt
PY Total Expenses	$356,450,352	PYTotalExpensesAmt
CY Total Expenses	$367,321,473	CYTotalExpensesAmt
PY Revenues Less Expenses	$82,404,409	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	$28,899,679	CYRevenuesLessExpensesAmt
Total Assets BOY	$382,344,839	TotalAssetsBOYAmt
Total Assets EOY	$454,102,204	TotalAssetsEOYAmt
Total Liabilities BOY	$146,112,465	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$185,710,815	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$236,232,374	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$268,391,389	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$65,088,628	ExpenseAmt
Grant	$45,038,188	GrantAmt
Revenue	$14,936,342	RevenueAmt
Desc	A) RESEARCH PROGRAMS: WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2019, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 44.3 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. BEAT AML MASTER TRIAL THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA(AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. MORE THAN 760 PATIENTS HAVE BEEN SCREENED IN 11 STUDY ARMS AT 16 CANCER CENTERS ACROSS THE COUNTRY. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGAINST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2019, FOR THE EIGHTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOL	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$147,721,907	ExpenseAmt
Grant	$101,378,520	GrantAmt
Desc	B) PATIENT & COMMUNITY SERVICES: PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE- TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER, LLS WEBSITE AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL. IN 2019, 717,119 FREE PRINTED DISEASE AND SUPPORT BOOKLETS AND 8,621 FACT SHEETS WERE ORDERED. ADDITIONALLY, THERE WERE 129,388 PAGE VIEWS OF THESE BOOKLETS AND FACT SHEETS ON THE LLS WEBSITE. EDUCATION MATERIALS ARE AVAILABLE TO DOWNLOAD OR ORDER AT WWW.LLS.ORG/BOOKLETS. MANY MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH, AND SELECT MATERIALS ARE AVAILABLE IN ADDITIONAL LANGUAGES. FINANCIAL ASSISTANCE IN 2019, A COMBINED 100,656,064 WAS DISBURSED TO PATIENTS THROUGH THE CO- PAY ASSISTANCE PROGRAM (97,150,904), THE LLS SUSAN LANG PATIENT TRAVEL ASSISTANCE PROGRAM (1,005,560), THE LLS URGENT NEED PROGRAM (1,168,000), AND THE LLS PATIENT AID PROGRAM (1,331,600). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2019, 97,150,904 WAS PROVIDED TO 27,034 PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2019, 1,105,560 WAS PROVIDED TO 2202 PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM. URGENT NEED PROGRAM THE URGENT NEED PROGRAM WAS ESTABLISHED TO HELP PEDIATRIC AND YOUNG ADULT BLOOD CANCER PATIENTS, OR ADULT BLOOD CANCER PATIENTS ENROLLED IN CLINICAL TRIALS, WHO ARE IN ACUTE FINANCIAL NEED. THE PROGRAM PROVIDES ELIGIBLE PATIENTS ASSISTANCE FOR NON-MEDICAL EXPENSES INCLUDING RENT, MORTGAGE, LODGING, UTILITIES, CHILDCARE, ELDER CARE, FOOD, TRANSPORTATION, CAR REPAIR, CAR INSURANCE, PHONE SERVICE, AND ACUTE DENTAL WORK RELATED TO TREATMENT. IN 2019, 1,168,000 WAS PROVIDED TO 2,357 PATIENTS THROUGH THE LLS URGENT NEED PROGRAM. PATIENT AID PROGRAM THE PATIENT AID PROGRAM PROVIDES FINANCIAL ASSISTANCE TO BLOOD CANCER PATIENTS. ELIGIBLE PATIENTS WILL RECEIVE A ONE-TIME 100 STIPEND TO HELP OFFSET EXPENSES. IN 2019, 1,331,600 WAS PROVIDED TO 13,316 PATIENTS THROUGH THE LLS PATIENT AID PROGRAM. COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY PATIENT ACCESS STAFF AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE AND ALLIED HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2019, 10 BCC CONFERENCES WERE HELD WITH 3,693 ATTENDEES. LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016 TO HONOR THE MEMORY OF MICHAEL GARIL, WHO WAS DIAGNOSED WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN 1974 AT THE AGE OF SEVEN. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2019, THERE WERE APPROXIMATELY 12,000 COMMUNITY MEMBERS AND 93,212 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 62,050 COMMENTS POSTED BY USERS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2019 LLS SUPPORTED OR HOSTED 127 FAMILY SUPPORT GROUPS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. IN ADDITION, LLS ALSO HOSTED 7 ONLINE NATIONAL CHAT GROUPS - I.E., VIRTUAL SUPPORT GROUPS - THAT ARE PROFESSIONALLY MODERATED. IN FY 2019, 3,817 INDIVIDUALS PARTICIPATED IN THESE CHATS. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS AND CAREGIVERS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT/CAREGIVER- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE PATIENT/CAREGIVER TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -OVER 1,500 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2019	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$40,007,613	ExpenseAmt
Desc	C) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS'S INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. INFORMATION SPECIALISTS MAY ALSO REFER PATIENTS AND CAREGIVERS TO A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER. THE NURSES IN THIS CENTER HAVE EXPERTISE IN THE BLOOD CANCERS AND PROVIDE PATIENTS AND THEIR CAREGIVERS WITH COMPREHENSIVE NAVIGATION TO FIND AND ENROLL IN AN APPROPRIATE CLINICAL TRIAL. AS PART OF THIS PROCESS, THE NURSES WORK CLOSELY WITH INFORMATION SPECIALISTS TO ADDRESS RESOURCE BARRIERS TO CLINICAL TRIAL ENROLLMENT. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2019: - 20,347 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 13,583 HOUSEHOLDS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. - 602 PATIENTS WORKED WITH A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; OVER 20% OF PATIENTS ASSISTED ENROLLED ON A CLINICAL TRIAL. LLS OFFERS PATIENTS AND CAREGIVERS FREE ONE-ON-ONE PHONE AND EMAIL CONSULTATIONS WITH A REGISTERED DIETITIAN WITH EXPERTISE IN ONCOLOGY NUTRITION. THIS SERVICE IS AVAILABLE TO ALL CANCER PATIENTS AND THEIR CAREGIVERS. IN FY 19 NEARLY 900 CONSULTATIONS WERE PROVIDED. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING FINANCIAL ASSISTANCE, INFORMATION SPECIALISTS, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH (AND ADDITIONAL LANGUAGES FOR SELECT MATERIALS), PERSONALIZED CLINICAL TRIAL NAVIGATION BY A REGISTERED NURSE, PERSONALIZED NUTRITION CONSULTATIONS BY A REGISTERED DIETICIAN AND CONTINUING EDUCATION PROGRAMS FOR HEALTHCARE PROFESSIONALS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS CONDUCTS TELEPHONE-WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES AS WELL AS SURVIVORSHIP ISSUES. PROGRAM PARTICIPANTS ARE GIVEN THE OPPORTUNITY TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS DELIVERED BY WORLD RENOWNED CLINICAL EXPERTS. UPCOMING AND ARCHIVED PROGRAMS ARE POSTED AT WWW.LLS.ORG/WEBCASTS. IN FY 2019: -LLS CONDUCTED 16 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 10,818 PARTICIPANTS -THERE WERE 29,521 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 2,324 VIRTUAL LECTURE VIEWS; 11,709 PODCAST DOWNLOADS; AND 32,254 VIDEO VIEWS.	Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

Field	Value	IRS element (for citing)
Expense	$13,833,686	ExpenseAmt
Desc	D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2019: -LLS PROVIDED 16 CME/CE-GRANTING IN-PERSON EDUCATIONAL PROGRAMS, WITH 3,660 HEALTHCARE PROFESSIONALS IN ATTENDANCE. -THERE WERE 28,877 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 10,602 VIRTUAL LECTURE VIEWS; AND 3,617 ONLINE VIDEO VIEWS FOR PROFESSIONALS. - LLS LAUNCHED A NEW PODCAST "TREATING BLOOD CANCERS" FOR HEALTHCARE PROFESSIONALS. IN ITS' INAUGURAL MONTHS THERE WERE 3,617 DOWNLOADS.	Desc

Field	Value	IRS element (for citing)
Total Other Prog Srvc Expense	$13,833,686	TotalOtherProgSrvcExpenseAmt
Total Program Service Expenses	$266,651,834	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Subject To Proxy Tax	false	SubjectToProxyTaxInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	Yes (true)	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Temp Or Permanent Endowments	Yes (true)	TempOrPermanentEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	false	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	false	ReportOtherAssetsInd
Report Other Liabilities	false	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	false	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (true)	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	Yes (true)	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	Yes (true)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (true)	ProfessionalFundraisingInd
Fundraising Activities	Yes (true)	FundraisingActivitiesInd
Gaming Activities	Yes (true)	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	Yes (true)	GrantsToOrganizationsInd
Grants To Individuals	Yes (true)	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With Officer Ent	false	BusinessRlnWithOfficerEntInd
Deductible Non Cash Contri	Yes (true)	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	Yes (true)	DisregardedEntityInd
Related Entity	Yes (true)	RelatedEntityInd
Related Organization Ctrl Ent	Yes (true)	RelatedOrganizationCtrlEntInd
Transaction With Control Ent	Yes (true)	TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	643	IRPDocumentCnt
IRP Document W2 G	5	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	1402	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	false	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	Yes (true)	ForeignFinancialAccountInd
Foreign Country	CA	ForeignCountryCd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (true)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (true)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	false	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	false	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	25	GoverningBodyVotingMembersCnt
Independent Voting Member	25	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	Yes (true)	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	false	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	Yes (true)	LocalChaptersInd
Policies Reference Chapters	Yes (true)	PoliciesReferenceChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AZ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DE	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ID	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	LA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NE	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Field	Value	IRS element (for citing)
Person	GORDON MILLER JR	PersonNm
Phone	9148218935	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	3 INTERNATIONAL DRIVE	AddressLine1Txt
City	RYE BROOK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10573	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (40 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd	Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd
LOUIS J DEGENNARO
PRESIDENT &	40.00	1.00	Yes (X)	$781,916	$0	$41,686
ROSEMARIE A LOFFREDO - END 33119
EVP CHIEF FI	40.00	1.00	Yes (X)	$405,232	$0	$22,698
GORDON MILLER JR
EVP CHIEF FI	40.00	1.00	Yes (X)	$283,759	$0	$39,673
ROBERT BECK - END 7519
EVP CHIEF OP	40.00	1.00	Yes (X)	$256,730	$0	$835
GWEN NICHOLS
EVP CHIEF ME	40.00			$481,501	$0	$38,386	Yes (X)
ALICE O'ROURKE - END 81518
EVP CHIEF DE	40.00			$387,674	$0	$31,477		Yes (X)
KATHY GRIESENBECK
EVP CHIEF RE	40.00			$377,786	$0	$36,695		Yes (X)
LEE M GREENBERGER
SVP CHIEF SC	40.00			$344,708	$0	$43,281		Yes (X)
THOMAS OSGOOD
EVP CHIEF HU	40.00			$312,125	$0	$24,807		Yes (X)
MARCIE KLEIN
EVP COMMUNIC	40.00			$292,249	$0	$35,199		Yes (X)
ANDREW S COCCARI - END 7618
EVP CHIEF PR	40.00			$191,345	$0	$26,623			Yes (X)
JORGE L BENITEZ
CHAIRMAN	6.00	2.00	Yes (X)	$0	$0	$0				Yes (X)
RALPH E LAWSON
SECRETARY/TR	4.00	2.00	Yes (X)	$0	$0	$0				Yes (X)
BART SICHEL
VICE CHAIR	4.00	2.00	Yes (X)	$0	$0	$0				Yes (X)
KATHLEEN MERIWETHER
AT LARGE	4.00		Yes (X)	$0	$0	$0				Yes (X)
WILLIAM G BEHNKE
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
PETER B BROCK
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
A DANA CALLOW JR
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
RENZO CANETTA MD
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
CASEY CUNNINGHAM
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
WILLIAM DALTON - END 10312018
BOD MEMBER	4.00	0.00		$0	$0	$0				Yes (X)
SAMUEL EBERTS - END 872019
BOD MEMBER	4.00	0.00		$0	$0	$0				Yes (X)
CHRISTOPHER FLOWERS
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
JANICE GABRILOVE
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
BERNARD H GARIL
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
JOHN GREENE
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
FRANCIE HELLER
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
MICHELLE LE BEAU PHD
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
CONNIE LINDSEY - END 7312018
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
RUBEN MESA
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
TED MOROZ
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
HARRY MOSELEY - END 1152020
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
LYNNE O'BRIEN
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
MARLA PERSKY
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
DONALD PROCTOR
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
ROBERT ROSEN
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
STEVEN T ROSEN
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
JEFF SACHS
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
KENNETH M SCHWARTZ
BOD MEMBER	4.00			$0	$0	$0				Yes (X)
KEITH S WHITE
BOD MEMBER	4.00			$0	$0	$0				Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$4,115,025	TotalReportableCompFromOrgAmt
Total Other Compensation	$341,360	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	202	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	Yes (true)	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
SYNEOS HEALTH LLC
75 REMITTANCE DRIVE SUITE 3160	CHICAGO	IL	606753160	CLINICAL TRIAL	$11,379,908
TARGETCW
9475 CHESEPAKE DRIVE	SAN DIEGO	CA	92123	TEMP STAFFING	$5,932,607
RESOURCE ONE
2900 EAST APACHE STREET	TULSA	OK	74110	DIRECT MARKETIN	$5,794,852
PATIENT ADVOCACY FOUNDATION
421 BUTLER FARM RD	HAMPTON	VA	23666	PAT ASSIST PROC	$4,175,809
NORTHGATE DIGITAL CORPORATION
301 SOUTH STATE STREET SUITE N-200	NEWTOWN	PA	189401956	SOFTWARE DEVELO	$3,013,897

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	194	CntrctRcvdGreaterThan100KCnt
Federated Campaigns	$946,462	FederatedCampaignsAmt
Fundraising	$191,114,487	FundraisingAmt
All Other Contributions	$180,689,145	AllOtherContributionsAmt
Noncash Contributions	$2,792,987	NoncashContributionsAmt
Total Contributions	$372,750,094	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

Field	Value	IRS element (for citing)
Desc	SERVICE REVENUE	Desc
Total Revenue Column	$14,936,342	TotalRevenueColumnAmt
Related Or Exempt Func Income	$14,936,342	RelatedOrExemptFuncIncomeAmt

Field	Value	IRS element (for citing)
Total Program Service Revenue	$14,936,342	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$7,317,868	TotalRevenueColumnAmt
Exclusion	$7,317,868	ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$4,512,294	TotalRevenueColumnAmt
Exclusion	$4,512,294	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$67,054,315	SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$65,752,269	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$1,302,046	SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,302,046	TotalRevenueColumnAmt
Exclusion	$1,302,046	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$23,715,013	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$191,114,487	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$28,271,666	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$4,556,653	TotalRevenueColumnAmt
Exclusion	-$4,556,653	ExclusionAmt

Field	Value	IRS element (for citing)
Gaming Gross Income	$231,305	GamingGrossIncomeAmt
Gaming Direct Expenses	$272,144	GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$40,839	TotalRevenueColumnAmt
Exclusion	-$40,839	ExclusionAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$396,221,152	TotalRevenueColumnAmt
Related Or Exempt Func Income	$14,936,342	RelatedOrExemptFuncIncomeAmt
Exclusion	$8,534,716	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$39,256,003	TotalAmt
Program Services	$39,256,003	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$101,378,520	TotalAmt
Program Services	$101,378,520	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$5,782,185	TotalAmt
Program Services	$5,782,185	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,189,690	TotalAmt
Program Services	$649,177	ProgramServicesAmt
Management And General	$1,286,985	ManagementAndGeneralAmt
Fundraising	$253,528	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$92,000,086	TotalAmt
Program Services	$50,721,909	ProgramServicesAmt
Management And General	$23,350,599	ManagementAndGeneralAmt
Fundraising	$17,927,578	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$2,397,769	TotalAmt
Program Services	$1,342,200	ProgramServicesAmt
Management And General	$579,851	ManagementAndGeneralAmt
Fundraising	$475,718	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$10,371,121	TotalAmt
Program Services	$5,831,569	ProgramServicesAmt
Management And General	$2,470,049	ManagementAndGeneralAmt
Fundraising	$2,069,503	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$6,246,242	TotalAmt
Program Services	$3,496,461	ProgramServicesAmt
Management And General	$1,510,525	ManagementAndGeneralAmt
Fundraising	$1,239,256	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$1,588,548	TotalAmt
Program Services	$953,129	ProgramServicesAmt
Management And General	$428,908	ManagementAndGeneralAmt
Fundraising	$206,511	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$409,901	TotalAmt
Management And General	$409,901	ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$900,103	TotalAmt
Program Services	$900,103	ProgramServicesAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$5,823,217	TotalAmt
Fundraising	$5,823,217	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$492,026	TotalAmt
Program Services	$361,673	ProgramServicesAmt
Management And General	$68,273	ManagementAndGeneralAmt
Fundraising	$62,080	FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$23,867,423	TotalAmt
Program Services	$15,065,765	ProgramServicesAmt
Management And General	$5,492,968	ManagementAndGeneralAmt
Fundraising	$3,308,690	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$9,777,174	TotalAmt
Program Services	$4,670,206	ProgramServicesAmt
Management And General	$1,065,057	ManagementAndGeneralAmt
Fundraising	$4,041,911	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$19,354,805	TotalAmt
Program Services	$9,221,114	ProgramServicesAmt
Management And General	$2,759,724	ManagementAndGeneralAmt
Fundraising	$7,373,967	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$7,082,941	TotalAmt
Program Services	$534,054	ProgramServicesAmt
Management And General	$5,261,209	ManagementAndGeneralAmt
Fundraising	$1,287,678	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$9,171,449	TotalAmt
Program Services	$5,857,079	ProgramServicesAmt
Management And General	$1,355,431	ManagementAndGeneralAmt
Fundraising	$1,958,939	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$8,414,576	TotalAmt
Program Services	$5,772,263	ProgramServicesAmt
Management And General	$1,283,222	ManagementAndGeneralAmt
Fundraising	$1,359,091	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$4,293,485	TotalAmt
Program Services	$278,064	ProgramServicesAmt
Management And General	$3,918,615	ManagementAndGeneralAmt
Fundraising	$96,806	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$796,510	TotalAmt
Program Services	$558,247	ProgramServicesAmt
Management And General	$118,868	ManagementAndGeneralAmt
Fundraising	$119,395	FundraisingAmt

Other Expenses OtherExpensesGrp (2 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
RESEARCH AND DEVELOPMENT	$10,467,600	$10,467,600
MISCELLANEOUS	$5,260,099	$3,554,513	$659,403	$1,046,183

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$367,321,473	TotalAmt
Program Services	$266,651,834	ProgramServicesAmt
Management And General	$52,019,588	ManagementAndGeneralAmt
Fundraising	$48,650,051	FundraisingAmt

Field	Value	IRS element (for citing)
Joint Costs	Yes (X)	JointCostsInd

Total Joint Costs TotalJointCostsGrp

Field	Value	IRS element (for citing)
Total	$12,818,016	TotalAmt
Program Services	$6,707,110	ProgramServicesAmt
Fundraising	$6,110,906	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$26,473,618	BOYAmt
EOY	$22,082,281	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$157,894,948	BOYAmt
EOY	$239,148,833	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$32,009,273	BOYAmt
EOY	$15,172,625	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$2,530,972	BOYAmt
EOY	$4,318,740	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$49,903,950	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$40,858,181	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$8,474,228	BOYAmt
EOY	$9,045,769	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$145,134,605	BOYAmt
EOY	$148,509,455	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$9,827,195	BOYAmt
EOY	$10,061,475	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
EOY	$5,763,026	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$382,344,839	BOYAmt
EOY	$454,102,204	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$25,315,604	BOYAmt
EOY	$27,935,486	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$105,033,884	BOYAmt
EOY	$144,560,351	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$15,762,977	BOYAmt
EOY	$13,214,978	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$146,112,465	BOYAmt
EOY	$185,710,815	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows SFAS117	Yes (X)	OrganizationFollowsSFAS117Ind

Unrestricted Net Assets UnrestrictedNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$143,923,113	BOYAmt
EOY	$174,200,077	EOYAmt

Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$92,309,261	BOYAmt
EOY	$94,191,312	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$236,232,374	BOYAmt
EOY	$268,391,389	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$382,344,839	BOYAmt
EOY	$454,102,204	EOYAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	Yes (X)	InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss	$28,899,679	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$3,259,336	NetUnrlzdGainsLossesInvstAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	false	FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$283,909,984	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$285,638,088	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$314,912,814	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$419,570,497	CurrentTaxYearMinus1YearAmt
Current Tax Year	$372,750,094	CurrentTaxYearAmt
Total	$1,676,781,477	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$283,909,984	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$285,638,088	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$314,912,814	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$419,570,497	CurrentTaxYearMinus1YearAmt
Current Tax Year	$372,750,094	CurrentTaxYearAmt
Total	$1,676,781,477	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$287,739,859	SubstantialContributorsTotAmt
Public Support Total170	$1,389,041,618	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$1,891,412	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$1,565,846	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$7,018,822	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$8,235,985	CurrentTaxYearMinus1YearAmt
Current Tax Year	$11,830,162	CurrentTaxYearAmt
Total	$30,542,227	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$56,829	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$19,529	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$25,439,044	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$70,000	CurrentTaxYearMinus1YearAmt
Total	$25,585,402	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$1,732,909,106	TotalSupportAmt
Gross Receipts Rltd Activities	$103,930,407	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.80160	PublicSupportCY170Pct
Public Support PY170	0.76140	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

Field	Value	IRS element (for citing)
Form And Line Reference	PART II, LINE 10	FormAndLineReferenceDesc
Explanation	OTHER MISC. REVENUE (YR 2014-2017) 265,206 TAP CONTRACTUAL RETURN (YR 2016) 25,320,196	ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Volunteers	Yes (true)	VolunteersInd
Paid Staff Or Management	Yes (true)	PaidStaffOrManagementInd
Media Advertisements	false	MediaAdvertisementsInd
Mailings Members	false	MailingsMembersInd
Publications Or Broadcast	Yes (true)	PublicationsOrBroadcastInd
Publications Or Broadcast	$378,846	PublicationsOrBroadcastAmt
Grants Other Organizations	false	GrantsOtherOrganizationsInd
Direct Contact Legislators	Yes (true)	DirectContactLegislatorsInd
Direct Contact Legislators	$288,980	DirectContactLegislatorsAmt
Rallies Demonstrations	Yes (true)	RalliesDemonstrationsInd
Rallies Demonstrations	$292,721	RalliesDemonstrationsAmt
Other Activities	Yes (true)	OtherActivitiesInd
Other Activities	$709,983	OtherActivitiesAmt
Total Lobbying Expenditures	$1,670,530	TotalLobbyingExpendituresAmt
Not Described Section501c3	false	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE C, PART II-B, LINE 1	FormAndLineReferenceDesc
Explanation	LLS IS A MEMBER OF A NUMBER OF COALITIONS AND MEMBERSHIPS INCLUDING FRIENDS OF CANCER RESEARCH, ONE VOICE AGAINST CANCER, NATIONAL HEALTH COUNCIL, THE CANCER LEADERSHIP COUNCIL, AMERICAN CHILDHOOD CANCER ORGANIZATION, PUBLIC AFFAIRS COUNCIL, PATIENT QUALITY OF LIFE COALITION, DEFENSE HEALTH RESEARCH CONSORTIUM, AND THE STATE ACCESS TO INNOVATIVE MEDICINES COALITION. LLS PARTNERS WITH LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA.	ExplanationTxt

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Collection Used Pub Exhibition	Yes (X)	CollectionUsedPubExhibitionInd
Solicited Assets Sale	false	SolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,192,807	BeginningYearBalanceAmt
Investment Earnings Or Losses	$292,934	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	-$304,999	GrantsOrScholarshipsAmt
Administrative Expenses	-$12,423	AdministrativeExpensesAmt
End Year Balance	$6,168,319	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$5,897,377	BeginningYearBalanceAmt
Contributions	$200	ContributionsAmt
Investment Earnings Or Losses	$546,324	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	-$237,896	GrantsOrScholarshipsAmt
Administrative Expenses	-$13,198	AdministrativeExpensesAmt
End Year Balance	$6,192,807	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,027,967	BeginningYearBalanceAmt
Contributions	$5,200	ContributionsAmt
Investment Earnings Or Losses	$119,369	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	-$240,000	GrantsOrScholarshipsAmt
Administrative Expenses	-$15,159	AdministrativeExpensesAmt
End Year Balance	$5,897,377	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,115,645	BeginningYearBalanceAmt
Contributions	$45,095	ContributionsAmt
Investment Earnings Or Losses	$116,288	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	-$240,000	GrantsOrScholarshipsAmt
Administrative Expenses	-$9,060	AdministrativeExpensesAmt
End Year Balance	$6,027,967	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,122,698	BeginningYearBalanceAmt
Investment Earnings Or Losses	$218,549	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	-$221,499	GrantsOrScholarshipsAmt
Administrative Expenses	-$4,103	AdministrativeExpensesAmt
End Year Balance	$6,115,645	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Prmnnt Endowment Balance EOY	0.46220	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.53780	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	false	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	false	EndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$2,342,106	OtherCostOrOtherBasisAmt
Depreciation	$1,403,320	DepreciationAmt
Book Value	$938,786	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$43,090,674	OtherCostOrOtherBasisAmt
Depreciation	$35,880,370	DepreciationAmt
Book Value	$7,210,304	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$4,471,170	OtherCostOrOtherBasisAmt
Depreciation	$3,574,491	DepreciationAmt
Book Value	$896,679	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$9,045,769	TotalBookValueLandBuildingsAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$418,779,817	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$3,259,336	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$10,371,748	DonatedServicesAndUseFcltsAmt
Other Revenue	$9,419,607	OtherRevenueAmt
Revenue Not Reported	$23,050,691	RevenueNotReportedAmt
Revenue Subtotal	$395,729,126	RevenueSubtotalAmt
Investment Expenses Not Incld	$492,026	InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt	$492,026	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$396,221,152	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$387,282,901	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$10,371,748	DonatedServicesUseFcltsAmt
Other Expenses Included	$10,044,313	OtherExpensesIncludedAmt
Expenses Not Reported	$20,416,061	ExpensesNotReportedAmt
Expenses Subtotal	$366,866,840	ExpensesSubtotalAmt
Investment Expenses Not Incld2	$492,026	InvestmentExpensesNotIncld2Amt
Other Expenses Not Included	-$37,393	OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt	$454,633	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$367,321,473	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (6 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
SCHEDULE D, PAGE 2, PART III, LINE 4	THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS.
SCHEDULE D, PAGE 2, PART V, LINE 4	LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS.
SCHEDULE D, PAGE 3, PART X	LLS, LLSRP, AND LLSRF QUALIFY AS CHARITABLE ORGANIZATIONS AS DEFINED BY INERNAL REVENUE CODE SECTION 501(C)(3) AND, ACCORDING, ARE EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE SECTION 501(A). ADDITIONALLY, SINCE THESE ORGANIZATIONS ARE PUBLICLY SUPPORTED, CONTRIBUTIONS QUALIFY FOR THE MAXIMUM CHARITABLE CONTRIBUTION DEDUCTION UNDER THE INTERNAL REVENUE CODE. LLSC IS REGISTERED AS A CHARITABLE ORGANIZATION UNDER THE INCOME TAX ACT (CANADA) AND IS, THEREFORE, NOT SUBJECT TO INCOME TAXES IF CERTAIN DISBURSMEENT REQUIREMENTS ARE MET. LLS AND ITS RELATED ENTITIES RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THERE WERE NO ENTITIES THAT RECOGNIZED ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2019 AND 2018.
SCHEDULE D, PAGE 4, PART XI, LINE 2D	LLS CANADA REVENUE 9,419,607
SCHEDULE D, PAGE 4, PART XII, LINE 2D	LLS CANADA EXPENSES 10,044,313
SCHEDULE D, PAGE 4, PART XII, LINE 4B	LLS CANADA FOREIGN CURRENCY ADJ -37,393

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (6 entries)

RegionRegionTxt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
NORTH AMERICA	RESEARCH FUNDING	RESEARCH GRANTS	$2,060,000
EUROPE	RESEARCH FUNDING	RESEARCH GRANTS	$1,601,053
EUROPE	INVESTMENTS	INVESTMENTS	$1,355,670
EAST ASIA	RESEARCH FUNDING	RESEARCH GRANTS	$2,001,132
CENTRAL AMERICA & CARIBBEAN	INVESTMENTS	INVESTMENTS	$7,474,713
MIDDLE EAST & NORTH AFRICA	RESEARCH FUNDING	RESEARCH GRANTS	$120,000

Field	Value	IRS element (for citing)
Subtotal Spent	$14,612,568	SubtotalSpentAmt
Total Spent	$14,612,568	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (16 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt	Valuation Method UsedValuationMethodUsedDesc
NORTH AMERICA	RESEARCH GRANT	$60,000	WIRE	ACCRUAL
EAST ASIA & PACIFIC	RESEARCH GRANT	$67,000	WIRE	ACCRUAL
EUROPE	RESEARCH GRANT	$199,924	WIRE	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	$500,000	CHECK	ACCRUAL
EUROPE	RESEARCH GRANT	$200,000	WIRE	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	$300,000	WIRE	ACCRUAL
EUROPE	THERAPY ACCELERATION	$1,000,000	WIRE	FMV
EAST ASIA & PACIFIC	RESEARCH GRANT	$7,970	WIRE	ACCRUAL
EAST ASIA & PACIFIC	RESEARCH GRANT	$199,987	WIRE	ACCRUAL
EAST ASIA & PACIFIC	RESEARCH GRANT	$67,000	WIRE	ACCRUAL
EAST ASIS & PACIFIC	RESEARCH GRANT	$200,000	WIRE	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	$1,200,000	CHECK	ACCRUAL
EUROPE	RESEARCH GRANT	$133,333	WIRE	ACCRUAL
EAST ASIA & PACIFIC	RESEARCH GRANT	$1,459,176	WIRE	ACCRUAL
MIDDLE EAST	RESEARCH GRANT	$120,000	WIRE	ACCRUAL
EUROPE	RESEARCH GRANT	$67,795	WIRE	ACCRUAL

Field	Value	IRS element (for citing)
Total Other Org	16	TotalOtherOrgCnt
Transfer To Foreign Corp	Yes (true)	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	Yes (true)	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	Yes (true)	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc

ExplanationExplanationTxt

SCHEDULE F, PAGE 1, PART I, LINE 2

FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS.

SCHEDULE F, PAGE 1, PART I, LINE 3

NORTH AMERICA 2,060,000 0 EUROPE 1,601,053 0 EUROPE 0 1,355,670 EAST ASIA 2,001,132 0 CENTRAL AMERICA & CARIBBEAN 0 7,474,713 MIDDLE EAST & NORTH AFRICA 120,000 0

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
Phone Solicitations	Yes (X)	PhoneSolicitationsInd
In Person Solicitations	Yes (X)	InPersonSolicitationsInd
Solicitation Of Non Govt Grants	Yes (X)	SolicitationOfNonGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (true)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (3 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	ActivityActivityTxt	Fundraiser Control Of FundsFundraiserControlOfFundsInd	Retained By ContractorRetainedByContractorAmt	Net To OrganizationNetToOrganizationAmt	Gross ReceiptsGrossReceiptsAmt
THOMPSON HABIB & DENISON
80 HAYDEN AVENUE SUITE 300	LEXINGTON	MA	02421	DIRECT MAI	false	$636,196	-$636,196
COINSTAR
1800 114TH AVENUE SE	BELLEVUE	WA	98004	COIN COLLE	false	$572,664	$5,035,630	$5,608,294
THE HERITAGE COMPANY INC
PO BOX 16325	LITTLE ROCK	AR	722316325	DIRECT MAI	false	$196,344	-$196,344

Field	Value	IRS element (for citing)
Total Gross Receipts	$5,608,294	TotalGrossReceiptsAmt
Total Retained By Contractors	$1,405,204	TotalRetainedByContractorsAmt
Total Net To Organization	$4,203,090	TotalNetToOrganizationAmt
All States	All States	AllStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	LAKE TAHOE BIKE	Event1Nm
Gross Receipts Event1	$3,774,761	GrossReceiptsEvent1Amt
Charitable Contri Event1	$3,371,512	CharitableContriEvent1Amt
Gross Revenue Event1	$403,249	GrossRevenueEvent1Amt
Non Cash Prizes Event1	$188,170	NonCashPrizesEvent1Amt
Rent Facility Costs Event1	$19,958	RentFacilityCostsEvent1Amt
Food And Beverage Event1	$57,813	FoodAndBeverageEvent1Amt
Entertainment Event1	$24,108	EntertainmentEvent1Amt
Other Direct Expenses Event1	$359,554	OtherDirectExpensesEvent1Amt
Event2	BLACK TIE	Event2Nm
Gross Receipts Event2	$2,894,684	GrossReceiptsEvent2Amt
Charitable Contri Event2	$1,993,008	CharitableContriEvent2Amt
Gross Revenue Event2	$901,676	GrossRevenueEvent2Amt
Non Cash Prizes Event2	$6,462	NonCashPrizesEvent2Amt
Rent Facility Costs Event2	$579,404	RentFacilityCostsEvent2Amt
Food And Beverage Event2	$327,130	FoodAndBeverageEvent2Amt
Entertainment Event2	$205,975	EntertainmentEvent2Amt
Other Direct Expenses Event2	$26,770	OtherDirectExpensesEvent2Amt
Other Events Total	647	OtherEventsTotalCnt
Gross Receipts Other Events	$208,160,055	GrossReceiptsOtherEventsAmt
Charitable Contri Other Events	$185,749,967	CharitableContriOtherEventsAmt
Gross Revenue Other Events	$22,410,088	GrossRevenueOtherEventsAmt
Non Cash Prizes Other Events	$5,506,546	NonCashPrizesOtherEventsAmt
Rent Fclty Costs Other Events	$10,920,094	RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events	$5,216,459	FoodAndBeverageOtherEventsAmt
Entertainment Other Events	$837,460	EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events	$3,995,763	OthDirectExpnssOtherEventsAmt
Gross Receipts Total	$214,829,500	GrossReceiptsTotalAmt
Charitable Contributions Tot	$191,114,487	CharitableContributionsTotAmt
Gross Revenue Total Events	$23,715,013	GrossRevenueTotalEventsAmt
Non Cash Prizes Total Events	$5,701,178	NonCashPrizesTotalEventsAmt
Rent Fclty Costs Total Events	$11,519,456	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$5,601,402	FoodAndBeverageTotalEventsAmt
Entertainment Total Events	$1,067,543	EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events	$4,382,087	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$28,271,666	DirectExpenseSummaryEventsAmt
Net Income Summary	-$4,556,653	NetIncomeSummaryAmt

Gaming Information GamingInformationGrp

Field	Value	IRS element (for citing)
Volunteer Labor Bingo	false	VolunteerLaborBingoInd
Volunteer Labor Pull Tabs	false	VolunteerLaborPullTabsInd
Gross Revenue Other Gaming	$231,305	GrossRevenueOtherGamingAmt
Cash Prizes Other Gaming	$10,135	CashPrizesOtherGamingAmt
Non Cash Prizes Other Gaming	$79,111	NonCashPrizesOtherGamingAmt
Oth Direct Expnss Other Gaming	$182,898	OthDirectExpnssOtherGamingAmt
Volunteer Labor Other Gaming	Yes (true)	VolunteerLaborOtherGamingInd
Volunteer Labor Other Gaming	0.39000	VolunteerLaborOtherGamingPct
Gross Revenue Total Gaming	$231,305	GrossRevenueTotalGamingAmt
Cash Prizes Total Gaming	$10,135	CashPrizesTotalGamingAmt
Non Cash Prizes Total Gaming	$79,111	NonCashPrizesTotalGamingAmt
Oth Direct Expnss Total Gaming	$182,898	OthDirectExpnssTotalGamingAmt
Direct Expense Summary Gaming	$272,144	DirectExpenseSummaryGamingAmt
Net Gaming Income Summary	-$40,839	NetGamingIncomeSummaryAmt

Field	Value	IRS element (for citing)
States Where Gaming Conducted	CT	StatesWhereGamingConductedCd
States Where Gaming Conducted	DC	StatesWhereGamingConductedCd
States Where Gaming Conducted	IA	StatesWhereGamingConductedCd
States Where Gaming Conducted	KY	StatesWhereGamingConductedCd
States Where Gaming Conducted	MI	StatesWhereGamingConductedCd
States Where Gaming Conducted	NJ	StatesWhereGamingConductedCd
States Where Gaming Conducted	NY	StatesWhereGamingConductedCd
States Where Gaming Conducted	PA	StatesWhereGamingConductedCd
States Where Gaming Conducted	TX	StatesWhereGamingConductedCd
States Where Gaming Conducted	WI	StatesWhereGamingConductedCd
Licensed	Yes (true)	LicensedInd
License Suspended Etc	false	LicenseSuspendedEtcInd
Gaming With Nonmembers	false	GamingWithNonmembersInd
Member Of Other Entity	false	MemberOfOtherEntityInd
Gaming Own Facility	0.25000	GamingOwnFacilityPct
Gaming Other Facility	0.75000	GamingOtherFacilityPct
Individual With Books	GORDON MILLER JR	IndividualWithBooksNm

Persons With Books US Address PersonsWithBooksUSAddress

Field	Value	IRS element (for citing)
Address Line1	3 INTERNATIONAL DRIVE SUITE 200	AddressLine1Txt
City	RYE BROOK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10573	ZIPCd

Field	Value	IRS element (for citing)
Cntrct With3rd Prty For Game Rev	false	CntrctWith3rdPrtyForGameRevInd
Gaming Manager Person	SEE SCHEDULE G PART IV	GamingManagerPersonNm
Charitable Distribution Rqr	false	CharitableDistributionRqrInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc

ExplanationExplanationTxt

SCHEDULE G, PAGE 2, PART III, LINE 9

PENNSYLVANIA, TEXAS, WISCONSIN

SCHEDULE G, PART IV

SCHEDULE G PART I, LINE 2B LLS USED MAIL AMERICA COMMUNICATIONS, THOMPSON, HABIB & DENSION, AND THE HERITAGE COMPANY FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. THESE PROGRAMS GENERATED GROSS RECEIPTS OF 20,238,259 DURING FISCAL YEAR 2019. LLS USED COINSTAR FOR ITS COIN COLLECTION DURING THE FISCAL YEAR 2019. SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF THE FAIR MARKET VALUE OF BENEFITS PROVIDED TO THE DONOR. SCHEDULE G PART III - LINE 16 THE LEUKEMIA AND LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF.

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (84 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Valuation Method UsedValuationMethodUsedDesc	Purpose Of GrantPurposeOfGrantTxt
ALBERT EINSTEIN COLLEGE OF MEDICINE
1300 MORRIS PARK AVE BELFER 1108	BRONX	NY	10461	472209056	3	$419,980	ACCRUAL	RESEARCH GRANT
ATRIUM HEALTH FOUNDATION
208 EAST BOULEVARD ATTN ELECTA MCP	CHARLOTTE	NC	28203	566060481	3	$82,500	ACCRUAL	RESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
P O BOX 301207	DALLAS	TX	753031207	741613878	3	$2,643,270	ACCRUAL	RESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE ROAD	DUARTE	CA	91010	953432210	3	$2,063,238	ACCRUAL	RESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
PO BOX 44253	SAN FRANCISCO	CA	941444253	941156365	3	$1,207,000	ACCRUAL	RESEARCH GRANT
BOSTON CHILDREN'S HOSPITAL
PO BOX 414413	BOSTON	MA	022414413	042774441	3	$487,000	ACCRUAL	RESEARCH GRANT
BOSTON UNIVERSITY RESEARCH ACCOUNTI
POBOX 28763	NEW YORK	NY	100878763	042103547	3	$600,666	ACCRUAL	RESEARCH GRANT
BRIGHAM AND WOMENS HOSPITAL
PO BOX 3149	BOSTON	MA	022413149	042312909	3	$610,000	ACCRUAL	RESEARCH GRANT
BROAD INSTITUTE INC
7 CAMBRIDGE CENTER	CAMBRIDGE	MA	02142	263428781	3	$60,000	ACCRUAL	RESEARCH GRANT
CHILDREN'S RESEARCH INSTITUTE
801 ROEDER RD SUITE 500	SILVER SPRING	MD	20910	521640403	3	$400,000	ACCRUAL	RESEARCH GRANT
CINCINNATI CHILDREN'S HOSPITAL MEDI
3333 BURNET AVENUE	CINCINATTI	OH	45229	310833936	3	$177,000	ACCRUAL	RESEARCH GRANT
CLEVELAND CLINIC FOUNDATION
PO BOX 931531	CLEVELAND	OH	44195	340714585	3	$200,000	ACCRUAL	RESEARCH GRANT
COLD SPRING HARBOR LABORATORY
1 BUNGTOWN ROAD PO BOX 100	COLD SPRING HARBOR	NY	11724	112013303	3	$110,000	ACCRUAL	RESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUE	BOSTON	MA	02215	042263040	3	$4,091,500	ACCRUAL	RESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
BP437 450 BROOKLINE AVENUE	BOSTON	MA	02215	042263040	3	$27,775	FMV	THERAPY ACCELERATION
EMORY UNIVERSITY
1599 CLIFTON RD NE 4TH FL 1599-0	ATLANTA	GA	311935084	582137993	3	$200,000	ACCRUAL	RESEARCH GRANT
FORTY SEVEN INC
1490 OBRIEN DRIVE SUITE A	MENLO PARK	CA	94025	474065674		$250,000	FMV	THERAPY ACCELERATION
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300	SEATTLE	WA	981091024	237156071	3	$723,178	ACCRUAL	RESEARCH GRANT
H LEE MOFFITT CANCER CENTER & RESE
PO BOX 742801	ATLANTA	GA	303742801	593238634	3	$1,999,997	ACCRUAL	RESEARCH GRANT
HACKENSACK MERIDIAN HEALTH
40 PROSPECT AVENUE	HACKENSACK	NJ	07601	010649794	3	$110,000	ACCRUAL	RESEARCH GRANT
HARVARD MEDICAL SCHOOL
PO BOX 415649	BOSTON	MA	022415649	042103580	3	$60,000	ACCRUAL	RESEARCH GRANT
ICAHN SCHOOL OF MEDICINE AT MOUNT S
ONE GUSTAVE L LEVY PLACE BOX 350	NEW YORK	NY	10029	136171197	3	$419,999	ACCRUAL	RESEARCH GRANT
INDIANA UNIVERSITY
509 E 3RD STREET	DETROIT	MI	482780867	356018940	3	$200,000	ACCRUAL	RESEARCH GRANT
INTERNATIONAL WALDENSTROM'S MACROGL
6144 CLARK CENTER AVE	SARASOTA	FL	34238	541784426	3	$125,000	ACCRUAL	RESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FL	NEW YORK	NY	10022	131623978	3	$1,647,000	ACCRUAL	RESEARCH GRANT
LA JOLLA INSTITUTE FOR ALLERGY AND
9420 ATHENA CIRCLE	LA JOLLA	CA	92037	330328688	3	$60,000	ACCRUAL	RESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
PO BOX 414876	BOSTON	MA	022414876	041564655	3	$225,000	ACCRUAL	RESEARCH GRANT
MASSACHUSETTS INSTITUTE OF TECHNOLO
77 MASSACHUSETTS AVE NE18-901	CAMBRIDGE	MA	02139	042103594	3	$200,000	ACCRUAL	RESEARCH GRANT
MAYO CLINIC ROCHESTER
PO BOX 860334	MINNEAPOLIS	MN	554860334	416011702	3	$400,000	ACCRUAL	RESEARCH GRANT
MONTEFIORE MEDICAL CENTER
111 EAST 210TH STREET	BRONX	NY	10467	131740114	3	$200,000	ACCRUAL	RESEARCH GRANT
MYELOPROLIFERATIVE NEOPLASMS RESEAR
180 N MICHIGAN AVENUE SUITE 1870	CHICAGO	IL	60601	364330967	3	$200,000	ACCRUAL	RESEARCH GRANT
NEMOURS ALFRED I DUPONT HOSPITAL F
PO BOX 414876	WILMINGTON	DE	19803	590634433	3	$39,060	ACCRUAL	RESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
PO BOX 415026	BOSTON	MA	022414150	135562308	3	$619,758	ACCRUAL	RESEARCH GRANT
NORTHWESTERN UNIVERSITY
633 CLARK - ROOM G547	EVANSTON	IL	60208	362167817	3	$377,000	ACCRUAL	RESEARCH GRANT
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK ROAD MAIL	PORTLAND	OR	97239	237083114	3	$325,000	ACCRUAL	RESEARCH GRANT
PERELMAN SCHOOL OF MEDICINE AT THE
3451 WALNUT STREET FRANKLIN BLDG P-	PHILADELPHIA	PA	191046205	231352685	3	$235,000	ACCRUAL	RESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MICHIG
BOX 223131	PITTSBURGH	PA	152512131	386006309	3	$925,094	ACCRUAL	RESEARCH GRANT
ROCKEFELLER UNIVERSITY
1230 YORK AVENUE BOX 82	NEW YORK	NY	10021	131624158	3	$266,999	ACCRUAL	RESEARCH GRANT
SANFORD BURNHAM PREBYS MEDICAL DISC
10901 NORTH TORREY PINES ROAD	LA JOLLA	CA	92037	510197108	3	$60,000	ACCRUAL	RESEARCH GRANT
SEATTLE CHILDREN'S HOSPITAL
4800 SAND POINT WAY NE	SEATTLE	WA	98105	911156519	3	$125,000	ACCRUAL	RESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
PO BOX 026338	NEW YORK	NY	10087	131924236	3	$2,506,332	ACCRUAL	RESEARCH GRANT
ST JUDE CHILDREN'S RESEARCH HOSPIT
PO BOX 1000 DEPT 949	MEMPHIS	TN	381480949	620646012	3	$376,999	ACCRUAL	RESEARCH GRANT
SUTRO
310 UTAH AVENUE 150 SOUTH	SAN FRANCISCO	CA	94080			$975,000	FMV	THERAPY ACCELERATION
TEMPLE UNIVERSITY
PO BOX 824242	PHILADELPHIA	PA	191824242	231365971	3	$200,000	ACCRUAL	RESEARCH GRANT
THE BOARD OF REGENTS OF THE UNIVERS
21 N PARK ST SUITE 6401	MADISON	WI	537151218	231365971	3	$200,000	ACCRUAL	RESEARCH GRANT
THE CHILDREN'S HOSPITAL OF PHILADEL
LOCKBOX 1457 PO BOX 8500	PHILADELPHIA	PA	191781457	396006492	3	$533,300	ACCRUAL	RESEARCH GRANT
THE JOHNS HOPKINS UNIVERSITY SCHOOL
12529 COLLECTIONS CENTER DRIVE CHIC	CHICAGO	IL	60693	231352166	3	$300,000	ACCRUAL	RESEARCH GRANT
THE OHIO STATE UNIVERSITY
1960 KENNY ROAD	COLUMBUS	OH	432101016	520595110	3	$409,224	ACCRUAL	RESEARCH GRANT
THE OHIO STATE UNIVERSITY
1960 KENNY ROAD	COLUMBUS	OH	432101016	520595110	3	$157,795	ACCRUAL	BEAT AML MASTER TRIA
THE REGENTS OF THE UNIVERSITY OF CA
BOX 0897 1855 FOLSOM STREET SUITE	LOS ANGELES	CA	900744872	316025986	3	$660,000	ACCRUAL	RESEARCH GRANT
THE SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORREY PINES ROAD TPC-7	LA JOLLA	CA	92037	946036493	3	$60,000	ACCRUAL	RESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789	NEW YORK	NY	100879789	330435954	3	$200,000	ACCRUAL	RESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
PO BOX 29789	NEW YORK	NY	100879789	135598093	3	$774,000	ACCRUAL	RESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
3451 WALNUT STREET FRANKLIN BLDG P-	PHILADELPHIA	PA	191046205	135598093	3	$527,000	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF ALABAMA AT BIRMIN
1530 3RD AVENUE SOUTH SUITE 1170	BIRMINGHAM	AL	352940111	231352685	3	$327,000	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092	CHICAGO	IL	60637	636005396	3	$227,000	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF IOWA
DIVISION OF SPONSORED PROGRAMS GILM	IOWA CITY	IA	52242	362177139	3	$200,000	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF NORTH CAROLINA AT
PO BOX 402420	ATLANTA	GA	303842420	426004813	3	$795,688	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
PO BOX 4266	HOUSTON	TX	772104266	566001393	3	$1,969,924	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF TEXAS SOUTHWESTER
PO BOX 841753	DALLAS	TX	752841753	746001118	3	$110,000	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF UTAH
201 S PRESIDENTS CIRCLE RM 145	SALT LAKE CITY	UT	841129003	756002868	3	$110,000	ACCRUAL	RESEARCH GRANT
THE WISTAR INSTITUTE
3601 SPRUCE STREET	PHILADELPHIA	PA	19104	876000525	3	$60,000	ACCRUAL	RESEARCH GRANT
TUFTS MEDICAL CENTER
800 WASHINGTON STREET 453	BOSTON	MA	02111	236434390	3	$52,500	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF ARKANSAS FOR MEDICAL
4301 W MARKHAM SLOT 545	LITTLE ROCK	AR	72205	042103634	3	$199,990	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF CALIFORNIA IRVINE
141 INNOVATION DRIVE SUITE 250 IR	IRVINE	CA	926977600	716056774	3	$200,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF CALIFORNIA SAN FRANC
BOX 0897 1855 FOLSOM STREET SUITE	LOS ANGELES	CA	900744872	952540117	3	$60,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF COLORADO DENVER ANSC
PO BOX 910238 DENVER CO 80291-0238	AURORA	CO	80045	946036493	3	$1,192,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF COLORADO-DENVER
12700 E 19TH AVENUE	AURORA	CO	80045	846000555	3	$200,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF FLORIDA
33 TIGERT HALL P O BOX 113001	GAINESVILLE	FL	326113001	846000555	3	$325,387	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF KENTUCKY
500 SOUTH LIMESTONE	LEXINGTON	KY	405060001	596002052	3	$59,993	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF MARYLAND BALTIMORE
PO BOX 41428	BALTIMORE	MD	212036428	616033693	3	$300,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF MASSACHUSETTS MEDICAL
55 LAKE AVENUE NORTH	WORCESTER	MA	016550002	526002033	3	$110,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF MIAMI
PO BOX 405803	ATLANTA	GA	303845803	043167352	3	$1,270,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF MINNESOTA TWIN CITIE
450 MCNAMARA ALUMNI CENTER	MINNEAPOLIS	MN	55414	590624458	3	$200,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF NOTRE DAME
511 MAIN BUILDING	NOTRE DAME	IN	46556	416007513	3	$200,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF SOUTHERN CALIFORNIA
1425 SAN PABLO ST LOS ANGELES CA	LOS ANGELES	CA	90089	350868188	3	$55,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF VIRGINIA
PO BOX 400195	CHARLOTTESVILLE	VA	229044195	951642394	3	$110,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF WISCONSIN AT MADISON
201 BASCOM HALL	MADISON	WI	53706	237173411	3	$67,000	ACCRUAL	RESEARCH GRANT
VAN ANDEL RESEARCH INSTITUTE
333 BOSTWICK AVE NE	GRAND RAPIDS	MI	49503	396006492	3	$110,000	ACCRUAL	RESEARCH GRANT
VANDERBILT UNIVERSITY MEDICAL CENTE
DEPT 1236 PO BOX 121236	DALLAS	TX	75312	522000820	3	$282,122	ACCRUAL	RESEARCH GRANT
VERASTEM
117 KENDRICK STREET SUITE 500	NEEDHAM HEIGHTS	MA	02494	620476822		$500,000	FMV	THERAPY ACCELERATION
WASHINGTON UNIVERSITY IN ST LOUIS
1 BROOKINGS DR	ST LOUIS	MO	63112	273269467	3	$220,000	ACCRUAL	RESEARCH GRANT
WASHINGTON UNIVERSITY SCHOOL OF MED
700 ROSEDALE AVENUE CAMPUS BOX 1034	ST LOUIS	MO	631121408	430653611	3	$352,346	ACCRUAL	RESEARCH GRANT
YALE UNIVERSITY
PO BOX 208327	NEW HAVEN	CT	065201873	430653611	3	$322,500	ACCRUAL	RESEARCH GRANT

Field	Value	IRS element (for citing)
Total501c3 Org	80	Total501c3OrgCnt
Total Other Org	3	TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (11 entries)

Grant TypeGrantTypeTxt	RecipientRecipientCnt	Cash GrantCashGrantAmt
COPAY ASSISTANCE CLL	5325	$16,044,725
COPAY ASSISTANCE LYMPHOMA	2450	$4,490,619
COPAY ASSISTANCE MDS	2989	$8,096,099
COPAY ASSISTANCE MYELOMA	12246	$57,109,928
COPAY ASSISTANCE MANTEL	1421	$3,388,994
COPAY ASSISTANCE WALDENST	147	$213,828
COPAY ASSISTANCE ALL	147	$153,615
COPAY ASSISTANCE AML	2309	$7,664,136
COPAY ASSISTANCE CML
PATIENT TRAVEL ASSISTANC	3354	$1,728,001
PATIENT AID	15656	$2,499,615

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE I, PAGE 1, PART I, LINE 2	FormAndLineReferenceDesc
Explanation	FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Form990 Of Other Organizations	Yes (X)	Form990OfOtherOrganizationsInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	Yes (true)	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	false	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	Yes (true)	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (11 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt
LOUIS J DEGENNARO
PRESIDENT & CEO	$630,962	$119,500	$31,454	$17,325	$24,361	$823,602
ROSEMARIE A LOFFREDO - END 33119
EVP CHIEF FIN OFFICE	$334,029	$47,450	$23,753	$9,771	$12,927	$427,930
GORDON MILLER JR
EVP CHIEF FIN OFFICE	$252,597	$30,338	$824	$13,750	$25,923	$323,432
ROBERT BECK - END 7519
EVP CHIEF OPER OFFIC	$211,585	$25,000	$20,145		$835	$257,565
GWEN NICHOLS
EVP CHIEF MED OFFICE	$386,438	$70,441	$24,622	$6,055	$32,331	$519,887
ALICE O'ROURKE - END 81518
EVP CHIEF DEV OFFICE	$175,641		$212,033	$7,710	$23,767	$419,151
KATHY GRIESENBECK
EVP CHIEF REL OFFICE	$315,071	$40,386	$22,329	$13,750	$22,945	$414,481
LEE M GREENBERGER
SVP CHIEF SCIEN OFFI	$277,118	$56,199	$11,391	$10,307	$32,974	$387,989
THOMAS OSGOOD
EVP CHIEF HUMAN RESO	$267,909	$37,212	$7,004	$5,201	$19,606	$336,932
MARCIE KLEIN
EVP COMMUNICATIONS	$254,475	$34,077	$3,697	$13,750	$21,449	$327,448
ANDREW S COCCARI - END 7618
EVP CHIEF PROD OFFIC	$190,403		$942	$6,697	$19,926	$217,968

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
SCHEDULE J, PAGE 1, PART I, LINE 4	ALICE O'ROURKE - END 8/15/18 208,984 0 0
SCHEDULE J, PAGE 1, PART I, LINE 7	SEVERANCE PAYMENTS RECEIVED ARE INCLUDED IN THE RESPECTIVE INDIVIDUAL'S TAXABLE INCOME AND REPORTED ON SCHEDULE J, PART II, COLUMN B (III). BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF THE EMPLOYEE INDIVIDUAL PERFORMANCE. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B)(II).

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	173	ContributionCnt
Noncash Contributions Rpt F990	$1,177,354	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FAIR MARKET VALUE	MethodOfDeterminingRevenuesTxt

Food Inventory FoodInventoryGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	114	ContributionCnt

Other Non Cash Contri Table OtherNonCashContriTableGrp (2 entries)

Non Cash CheckboxNonCashCheckboxInd	DescDesc	ContributionContributionCnt	Noncash Contributions Rpt F990NoncashContributionsRptF990Amt
Yes (X)	PRINTED ITEMS	20
Yes (X)	VARIOUS	175	$1,615,633

Field	Value	IRS element (for citing)
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	Yes (true)	ReviewProcessUnusualNCGiftsInd
Third Parties Used	false	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE M, PAGE 2, PART II	FormAndLineReferenceDesc
Explanation	PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. PART I, LINE 33 - EXPLANATION FOR NOT REPORTING REVENUE LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (12 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PAGE 2, PART III, LINE 4A	A) RESEARCH PROGRAMS: WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2019, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 44.3 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. BEAT AML MASTER TRIAL THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA(AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. MORE THAN 760 PATIENTS HAVE BEEN SCREENED IN 11 STUDY ARMS AT 16 CANCER CENTERS ACROSS THE COUNTRY. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGAINST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2019, FOR THE EIGHTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOL
FORM 990, PAGE 2, PART III, LINE 4B	B) PATIENT & COMMUNITY SERVICES: PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE- TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER, LLS WEBSITE AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL. IN 2019, 717,119 FREE PRINTED DISEASE AND SUPPORT BOOKLETS AND 8,621 FACT SHEETS WERE ORDERED. ADDITIONALLY, THERE WERE 129,388 PAGE VIEWS OF THESE BOOKLETS AND FACT SHEETS ON THE LLS WEBSITE. EDUCATION MATERIALS ARE AVAILABLE TO DOWNLOAD OR ORDER AT WWW.LLS.ORG/BOOKLETS. MANY MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH, AND SELECT MATERIALS ARE AVAILABLE IN ADDITIONAL LANGUAGES. FINANCIAL ASSISTANCE IN 2019, A COMBINED 100,656,064 WAS DISBURSED TO PATIENTS THROUGH THE CO- PAY ASSISTANCE PROGRAM (97,150,904), THE LLS SUSAN LANG PATIENT TRAVEL ASSISTANCE PROGRAM (1,005,560), THE LLS URGENT NEED PROGRAM (1,168,000), AND THE LLS PATIENT AID PROGRAM (1,331,600). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2019, 97,150,904 WAS PROVIDED TO 27,034 PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2019, 1,105,560 WAS PROVIDED TO 2202 PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM. URGENT NEED PROGRAM THE URGENT NEED PROGRAM WAS ESTABLISHED TO HELP PEDIATRIC AND YOUNG ADULT BLOOD CANCER PATIENTS, OR ADULT BLOOD CANCER PATIENTS ENROLLED IN CLINICAL TRIALS, WHO ARE IN ACUTE FINANCIAL NEED. THE PROGRAM PROVIDES ELIGIBLE PATIENTS ASSISTANCE FOR NON-MEDICAL EXPENSES INCLUDING RENT, MORTGAGE, LODGING, UTILITIES, CHILDCARE, ELDER CARE, FOOD, TRANSPORTATION, CAR REPAIR, CAR INSURANCE, PHONE SERVICE, AND ACUTE DENTAL WORK RELATED TO TREATMENT. IN 2019, 1,168,000 WAS PROVIDED TO 2,357 PATIENTS THROUGH THE LLS URGENT NEED PROGRAM. PATIENT AID PROGRAM THE PATIENT AID PROGRAM PROVIDES FINANCIAL ASSISTANCE TO BLOOD CANCER PATIENTS. ELIGIBLE PATIENTS WILL RECEIVE A ONE-TIME 100 STIPEND TO HELP OFFSET EXPENSES. IN 2019, 1,331,600 WAS PROVIDED TO 13,316 PATIENTS THROUGH THE LLS PATIENT AID PROGRAM. COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY PATIENT ACCESS STAFF AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE AND ALLIED HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2019, 10 BCC CONFERENCES WERE HELD WITH 3,693 ATTENDEES. LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016 TO HONOR THE MEMORY OF MICHAEL GARIL, WHO WAS DIAGNOSED WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN 1974 AT THE AGE OF SEVEN. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2019, THERE WERE APPROXIMATELY 12,000 COMMUNITY MEMBERS AND 93,212 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 62,050 COMMENTS POSTED BY USERS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2019 LLS SUPPORTED OR HOSTED 127 FAMILY SUPPORT GROUPS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. IN ADDITION, LLS ALSO HOSTED 7 ONLINE NATIONAL CHAT GROUPS - I.E., VIRTUAL SUPPORT GROUPS - THAT ARE PROFESSIONALLY MODERATED. IN FY 2019, 3,817 INDIVIDUALS PARTICIPATED IN THESE CHATS. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS AND CAREGIVERS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT/CAREGIVER- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE PATIENT/CAREGIVER TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -OVER 1,500 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2019
FORM 990, PAGE 2, PART III, LINE 4C	C) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS'S INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. INFORMATION SPECIALISTS MAY ALSO REFER PATIENTS AND CAREGIVERS TO A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER. THE NURSES IN THIS CENTER HAVE EXPERTISE IN THE BLOOD CANCERS AND PROVIDE PATIENTS AND THEIR CAREGIVERS WITH COMPREHENSIVE NAVIGATION TO FIND AND ENROLL IN AN APPROPRIATE CLINICAL TRIAL. AS PART OF THIS PROCESS, THE NURSES WORK CLOSELY WITH INFORMATION SPECIALISTS TO ADDRESS RESOURCE BARRIERS TO CLINICAL TRIAL ENROLLMENT. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2019: - 20,347 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 13,583 HOUSEHOLDS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. - 602 PATIENTS WORKED WITH A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; OVER 20% OF PATIENTS ASSISTED ENROLLED ON A CLINICAL TRIAL. LLS OFFERS PATIENTS AND CAREGIVERS FREE ONE-ON-ONE PHONE AND EMAIL CONSULTATIONS WITH A REGISTERED DIETITIAN WITH EXPERTISE IN ONCOLOGY NUTRITION. THIS SERVICE IS AVAILABLE TO ALL CANCER PATIENTS AND THEIR CAREGIVERS. IN FY 19 NEARLY 900 CONSULTATIONS WERE PROVIDED. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING FINANCIAL ASSISTANCE, INFORMATION SPECIALISTS, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH (AND ADDITIONAL LANGUAGES FOR SELECT MATERIALS), PERSONALIZED CLINICAL TRIAL NAVIGATION BY A REGISTERED NURSE, PERSONALIZED NUTRITION CONSULTATIONS BY A REGISTERED DIETICIAN AND CONTINUING EDUCATION PROGRAMS FOR HEALTHCARE PROFESSIONALS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS CONDUCTS TELEPHONE-WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES AS WELL AS SURVIVORSHIP ISSUES. PROGRAM PARTICIPANTS ARE GIVEN THE OPPORTUNITY TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS DELIVERED BY WORLD RENOWNED CLINICAL EXPERTS. UPCOMING AND ARCHIVED PROGRAMS ARE POSTED AT WWW.LLS.ORG/WEBCASTS. IN FY 2019: -LLS CONDUCTED 16 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 10,818 PARTICIPANTS -THERE WERE 29,521 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 2,324 VIRTUAL LECTURE VIEWS; 11,709 PODCAST DOWNLOADS; AND 32,254 VIDEO VIEWS.
FORM 990, PAGE 2, PART III, LINE 4D	D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2019: -LLS PROVIDED 16 CME/CE-GRANTING IN-PERSON EDUCATIONAL PROGRAMS, WITH 3,660 HEALTHCARE PROFESSIONALS IN ATTENDANCE. -THERE WERE 28,877 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 10,602 VIRTUAL LECTURE VIEWS; AND 3,617 ONLINE VIDEO VIEWS FOR PROFESSIONALS. - LLS LAUNCHED A NEW PODCAST "TREATING BLOOD CANCERS" FOR HEALTHCARE PROFESSIONALS. IN ITS' INAUGURAL MONTHS THERE WERE 3,617 DOWNLOADS.
FORM 990, PART V, LINE 4B	CANADA
FORM 990, PAGE 6, PART VI, LINE 4	IN FY2019, THE LLS MANAGEMENT AND THE BOARD OF DIRECTORS AMENDED THE BI- LAWS OF THE LLS TO DO THE FOLLOWING: 1) ELIMINATED ALL CLASS A AND CLASS B MEMBERS. 2) ALLOWED BOARD OF DIRECTOR OFFICERS TO EXCEED THEIR TERM LIMITS FOR SERVING IF APPROVED BY TWO-THIRDS OF THE BOARD. 3) CONSOLIDATED THE FINANCE COMMITTEE AND AUDIT COMMITTEE INTO A SINGLE FINANCE AND AUDIT COMMITTEE 4) CONSOLIDATED VARIOUS OPERATING COMMITTEES.
FORM 990, PAGE 6, PART VI, LINE 11B	THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, VICE PRESIDENT, CONTROLLER, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS.
FORM 990, PAGE 6, PART VI, LINE 12C	ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE.
FORM 990, PAGE 6, PART VI, LINE 15A	THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS, MONITORS, AND APPROVES THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2019 THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THEIR COMPENSATION MARKET LEVELS AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET, APPROVED AND DOCUMENTED THE PROCESS IN THE COMMITTEE MINUTES.
FORM 990, PAGE 6, PART VI, LINE 15B	IN 2019, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS OF OTHER OFFICERS AND KEY EMPLOYEES AND TO APPROVE THE PRESIDENT AND CEO'S RECOMMENDATIONS ON THEIR COMPENSATION LEVELS.
FORM 990, PAGE 6, PART VI, LINE 17	ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA
FORM 990, PAGE 6, PART VI, LINE 19	THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE UPON REQUEST FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990.

Schedule R IRS990ScheduleR

Id Disregarded Entities IdDisregardedEntitiesGrp (4 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Primary ActivitiesPrimaryActivitiesTxt	Legal Domicile StateLegalDomicileStateCd	Total IncomeTotalIncomeAmt	End Of Year AssetsEndOfYearAssetsAmt	Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt
BEAT AML LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY	$15,691,417	$8,786,795	LLS
LLS PEDAL INITIATIVE LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY	-$816,049	$48,420	LLS
LLS TAP LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY			LLS
LLS TAP X4 LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY	$1,138,000	$4,680,000	LLS

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	EINEIN	Primary ActivitiesPrimaryActivitiesTxt	Legal Domicile StateLegalDomicileStateCd	Exempt Code SectionExemptCodeSectionTxt	Public Charity StatusPublicCharityStatusTxt	Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt	Controlled OrganizationControlledOrganizationInd	Address Line1ForeignAddress/AddressLine1Txt	CityForeignAddress/CityNm	CountryForeignAddress/CountryCd	Foreign PostalForeignAddress/ForeignPostalCd	Legal Domicile Foreign CountryLegalDomicileForeignCountryCd
THE LLS RESEARCH PROGRAMS INC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	133470494	PART VII	DE	501C3	12A	LLS INC	Yes (true)
THE LLS RESEARCH FOUNDATION
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	133709252	PART VII	DE	501C3	12A	LLS INC	Yes (true)
THE LLS OF CANADA
					PART VII				NA	false	804 2 LANSING SQUARE	TORONTO	CA	M2J4P8	CA

Field	Value	IRS element (for citing)
Receipt Of Int Annts Rnts Rylts	false	ReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth Org	false	GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth Org	false	GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other Org	false	LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth Org	false	LoansOrGuaranteesFromOthOrgInd
Div Related Organization	false	DivRelatedOrganizationInd
Asset Sale To Other Org	false	AssetSaleToOtherOrgInd
Asset Purchase From Other Org	false	AssetPurchaseFromOtherOrgInd
Asset Exchange	false	AssetExchangeInd
Rental Of Facilities To Oth Org	false	RentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth Org	false	RentalOfFcltsFromOthOrgInd
Perform Of Services For Oth Org	false	PerformOfServicesForOthOrgInd
Perform Of Services By Other Org	false	PerformOfServicesByOtherOrgInd
Sharing Of Facilities	false	SharingOfFacilitiesInd
Paid Employees Sharing	false	PaidEmployeesSharingInd
Reimbursement Paid To Other Org	false	ReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other Org	Yes (true)	ReimbursementPaidByOtherOrgInd
Transfer To Other Org	false	TransferToOtherOrgInd
Transfer From Other Org	false	TransferFromOtherOrgInd

Transactions Related Org TransactionsRelatedOrgGrp

Other Organization Name OtherOrganizationName

Field	Value	IRS element (for citing)
Business Name Line1	LLS CANADA	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Transaction Type	Q	TransactionTypeTxt
Involved	$223,331	InvolvedAmt
Method Of Amount Determination	COST	MethodOfAmountDeterminationTxt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE R	FormAndLineReferenceDesc
Explanation	THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC.	ExplanationTxt